Korzyści ze stosowania winpocetyny Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lip 22, 2024
Słowa kluczowe:
winpocetyna, udar mózgu, zaburzenia poznawcze, nadciśnienie, zawroty głowy, niedosłuch, drgawki, neuroprotekcja
##plugins.themes.bootstrap3.article.main##
Abstrakt
Od wprowadzenia na rynek w 1978 r. winpocetyna jest szeroko stosowana w wielu schorzeniach neurologicznych, przede wszystkim z uwagi na swoje działanie rozszerzające mózgowe naczynia krwionośne. Badania wykonywane w kolejnych latach wykazywały ponadto, że winpocetyna działa przeciwzapalnie przez hamowanie transkrypcji jądrowego czynnika κΒ (NF-κΒ), a także ma znaczącą aktywność neuroprotekcyjną, m.in. przez zdolność hamowania napięciowozależnych kanałów sodowych i wapniowych. Badania kliniczne z ostatnich kilkunastu latach potwierdziły korzystny profil terapeutyczny winpocetyny. Korzyści ze stosowania winpocetyny wykazano u pacjentów z udarem mózgu, z zaburzeniami poznawczymi (zwłaszcza skojarzonymi z nadciśnieniem tętniczym), a także u pacjentów z łagodną postacią deficytów poznawczych. Winpocetyna przynosi również korzystne efekty u pacjentów z zawrotami głowy lub niedosłuchem oraz u pacjentów z epizodami padaczkowymi pojawiającymi się w przebiegu chorób ośrodkowego układu nerwowego. Z uwagi na niewielką liczbę interakcji lekowych winpocetyna może być stosowana w terapii polimodalnej wraz z innymi lekami wykorzystywanymi w leczeniu chorób ośrodkowego układu nerwowego
##plugins.themes.bootstrap3.article.details##
Jak cytować
Frankiewicz, T. (2024). Korzyści ze stosowania winpocetyny . Medycyna Faktów . Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/3132
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. NFZ o zdrowiu. Udar niedokrwienny mózgu. https://ezdrowie.gov.pl/portal/home/badania-i-dane/zdrowe-dane/raporty/nfz-o-zdrowiu-udar-niedokrwienny-mozgu.
2. Ahn HS, Crim W, Romano M et al. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 1989; 38: 3331-9.
3. Dong ZC, Shi Y, Juan L. Synthesis and pharmacological activity of vinpocetine derivatives. RSC Adv. 2024; 14: 7981.
4. Ahmad N, Lesa KN, Sudarmanto A. The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review. Front Pharmacol. 2022; 13: 1070677. http://doi.org/10.3389/fphar.2022.1070677.
5. Zhang YS, Li JD, Yan C. An update on vinpocetine: new discoveries and clinical implications. Eur J Pharmacol. 2018; 819: 30-4.
6. Bönöczk P, Gulyaś B, Adam-Vizi V. Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Br Res Bull. 2000; 53(3): 245-54.
7. Jeon KI, Xu X, Aizawa T et al. Vinpocetine inhibits NF-κBdependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci USA. 20210; 107: 9795-800.
8. Lamar J-C, Poignet H, Beaughard M. Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischaemia. Drug Dev Res. 1988; 14: 297-304.
9. Sitges M, Sanchez-Tafolla BM, Chiu LM. Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs. Epilepsy Res. 2011; 96: 257-66.
10. Salińska E, Danysz W, Łazarewicz W. The role of excitotoxicity in neurodegeneration. Folia Neuropathol. 2005; 43(4): 322-39.
11. Santos MS, Durate AI, Moreira PI. Synaptosomal response to oxidative stress: Effect of vinpocetine. Free Radical Res. 2000; 32: 57-66.
12. Hadjiev D, Yancheva S. Rheoencephalographic and psychological studies with etyl apovincaminate in cerebral vascular insufficiency. Drug Res. 1976; 26: 1947-50.
13. Solti F, Iskum M, Czako E. Effect of ethyl apovincaminate on the cerebral circulation. Drug Res. 1976; 26: 1945-7.
14. Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60 (7-8): 301-10.
15. Werner J, Apecechea M, Schaltenbrand R et al. Clinical study to evaluate the efficacy and tolerance of vinpocetine i.v. added to standard therapy in patients suffering from an acute apoplectic insult Senile Dementias: early detection. John Libbey Eurotext. 1986; 1: 636-41.
16. Fenzl E, Apecechea M, Schaltenbrand R. Efficacy and tolerance of vinpocetine administered intravenously, in addition of standard therapy, to patients suffering from an apoplectic insult. W: Pharmacology of Cerebral Ischemia. Proceedings of the International Symposium on Pharmacology of Cerebral Ischemia. Krieglstein J (ed). Elsevier, New York 1986; 430-434.
17. Blaha L, Erzigkeit H, Adamczyk A. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Human Psychopharmacology. 1989; 4: 103-111.
18. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991; 6(1): 31-43.
19. Macrez R, Ali C, Toutirais O et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol. 2011; 10: 471-80.
20. Zarruk JG, Greenhalgh AD, David S. Microglia and macrophages differ in their inflammatory profile after permanent brain ischemia. Exp Neurol. 2018; 301: 120-32.
21. Wu LR, Liu L, Xiong XY et al. Vinpocetine alleviate cerebral ischemia/reperfusion injury by down-regulating TLR4/MyD88/NF-κB signaling. Oncotarget. 2017; 8: 80315-24.
22. Zhang F, Yan C, Wei C. Vinpocetine Inhibits NF-κB-Dependent Inflammation in Acute Ischemic Stroke Patients. Transl Stroke Res. 2018; 9: 174-184.
23. Mamcarz A, Mastalerz-Migas A, Mirowska-Guzel D. Stanowisko interdyscyplinarnego zespołu ekspertów dotyczące leczenia pacjentów z nadciśnieniem tętniczym i współistniejącymi zaburzeniami funkcji poznawczych w codziennej praktyce lekarskiej. Lekarz POZ. 2017; 3(6): 369-82.
24. Taiji H. Clinical study of vinpocetine in the treatment of vertigo. Pharmacology and Treatment. 1986; 14(2): 577-89.
25. Smartsev IN, Zhivolupov SA, Butakova S. Efficiency of long-term vinpocetine administration in the treatment of dizziness and associated statodynamic disorders in patients with chronic cerebrovascular insufficiency (EDELWEISS study). 2019; 11(1): 36-47.
26. Garza-Morales S, Briceno-Gonzalez, Ceja-Moreno E. Extended-release vinpocetine: a possible adjuvant treatment for focal onset epileptic seizures. Bol Med Hosp Infant Mex. 2019; 76(5): 215-24.
27. Gjerulfsen CE, Mieszczanek TS , Johannsen KM. Vinpocetine improved neuropsychiatric and epileptic outcomes in a patient with a GABRA1 loss-of-function variant. Ann Clin Transl Neurol. 2023; 10(8): 1493-8.
28. Jasper A. Action of cavinton on hearing defects of different origin. Hung Med. 1978; 26: 181-4.
29. Gutierrez-Farfan I, Reyes-Legoreta C, Solis-Olguin M. Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study. J Pharmacol Sci 2021;145: 313-18.
30. Panda PK, Ramachandran A, Panda P. Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta‑Analysis. Neurocrit Care. 2022; 37: 314-25.
2. Ahn HS, Crim W, Romano M et al. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 1989; 38: 3331-9.
3. Dong ZC, Shi Y, Juan L. Synthesis and pharmacological activity of vinpocetine derivatives. RSC Adv. 2024; 14: 7981.
4. Ahmad N, Lesa KN, Sudarmanto A. The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review. Front Pharmacol. 2022; 13: 1070677. http://doi.org/10.3389/fphar.2022.1070677.
5. Zhang YS, Li JD, Yan C. An update on vinpocetine: new discoveries and clinical implications. Eur J Pharmacol. 2018; 819: 30-4.
6. Bönöczk P, Gulyaś B, Adam-Vizi V. Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Br Res Bull. 2000; 53(3): 245-54.
7. Jeon KI, Xu X, Aizawa T et al. Vinpocetine inhibits NF-κBdependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci USA. 20210; 107: 9795-800.
8. Lamar J-C, Poignet H, Beaughard M. Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischaemia. Drug Dev Res. 1988; 14: 297-304.
9. Sitges M, Sanchez-Tafolla BM, Chiu LM. Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs. Epilepsy Res. 2011; 96: 257-66.
10. Salińska E, Danysz W, Łazarewicz W. The role of excitotoxicity in neurodegeneration. Folia Neuropathol. 2005; 43(4): 322-39.
11. Santos MS, Durate AI, Moreira PI. Synaptosomal response to oxidative stress: Effect of vinpocetine. Free Radical Res. 2000; 32: 57-66.
12. Hadjiev D, Yancheva S. Rheoencephalographic and psychological studies with etyl apovincaminate in cerebral vascular insufficiency. Drug Res. 1976; 26: 1947-50.
13. Solti F, Iskum M, Czako E. Effect of ethyl apovincaminate on the cerebral circulation. Drug Res. 1976; 26: 1945-7.
14. Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60 (7-8): 301-10.
15. Werner J, Apecechea M, Schaltenbrand R et al. Clinical study to evaluate the efficacy and tolerance of vinpocetine i.v. added to standard therapy in patients suffering from an acute apoplectic insult Senile Dementias: early detection. John Libbey Eurotext. 1986; 1: 636-41.
16. Fenzl E, Apecechea M, Schaltenbrand R. Efficacy and tolerance of vinpocetine administered intravenously, in addition of standard therapy, to patients suffering from an apoplectic insult. W: Pharmacology of Cerebral Ischemia. Proceedings of the International Symposium on Pharmacology of Cerebral Ischemia. Krieglstein J (ed). Elsevier, New York 1986; 430-434.
17. Blaha L, Erzigkeit H, Adamczyk A. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Human Psychopharmacology. 1989; 4: 103-111.
18. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991; 6(1): 31-43.
19. Macrez R, Ali C, Toutirais O et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol. 2011; 10: 471-80.
20. Zarruk JG, Greenhalgh AD, David S. Microglia and macrophages differ in their inflammatory profile after permanent brain ischemia. Exp Neurol. 2018; 301: 120-32.
21. Wu LR, Liu L, Xiong XY et al. Vinpocetine alleviate cerebral ischemia/reperfusion injury by down-regulating TLR4/MyD88/NF-κB signaling. Oncotarget. 2017; 8: 80315-24.
22. Zhang F, Yan C, Wei C. Vinpocetine Inhibits NF-κB-Dependent Inflammation in Acute Ischemic Stroke Patients. Transl Stroke Res. 2018; 9: 174-184.
23. Mamcarz A, Mastalerz-Migas A, Mirowska-Guzel D. Stanowisko interdyscyplinarnego zespołu ekspertów dotyczące leczenia pacjentów z nadciśnieniem tętniczym i współistniejącymi zaburzeniami funkcji poznawczych w codziennej praktyce lekarskiej. Lekarz POZ. 2017; 3(6): 369-82.
24. Taiji H. Clinical study of vinpocetine in the treatment of vertigo. Pharmacology and Treatment. 1986; 14(2): 577-89.
25. Smartsev IN, Zhivolupov SA, Butakova S. Efficiency of long-term vinpocetine administration in the treatment of dizziness and associated statodynamic disorders in patients with chronic cerebrovascular insufficiency (EDELWEISS study). 2019; 11(1): 36-47.
26. Garza-Morales S, Briceno-Gonzalez, Ceja-Moreno E. Extended-release vinpocetine: a possible adjuvant treatment for focal onset epileptic seizures. Bol Med Hosp Infant Mex. 2019; 76(5): 215-24.
27. Gjerulfsen CE, Mieszczanek TS , Johannsen KM. Vinpocetine improved neuropsychiatric and epileptic outcomes in a patient with a GABRA1 loss-of-function variant. Ann Clin Transl Neurol. 2023; 10(8): 1493-8.
28. Jasper A. Action of cavinton on hearing defects of different origin. Hung Med. 1978; 26: 181-4.
29. Gutierrez-Farfan I, Reyes-Legoreta C, Solis-Olguin M. Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study. J Pharmacol Sci 2021;145: 313-18.
30. Panda PK, Ramachandran A, Panda P. Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta‑Analysis. Neurocrit Care. 2022; 37: 314-25.